ARD 501
Alternative Names: ARD-501Latest Information Update: 02 Feb 2024
Price :
$50 *
At a glance
- Originator Aardvark Therapeutics
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pervasive child development disorders
Most Recent Events
- 30 Jan 2024 Phase-II clinical trials in Pervasive child development disorders (In adults) in USA (PO) (NCT06126653)
- 13 Nov 2023 Aardvark Therapeutics plans a phase II trial in Pervasive child development disorders (In children, In adults) in USA (PO) in November 2023 (NCT06126653)
- 06 Apr 2023 Phase-I clinical trials in Autistic disorder in USA (PO) (Aardvark Therapeutics pipeline, April 2023)